By Brenda Potts
Publication Date: 2025-12-09 16:00:00
The convergence of digital transformation and the GenAI revolution creates an unprecedented opportunity for accelerating progress in precision health. Precision immunotherapy is a poster child for this transformation. Emerging technologies such as multiplex immunofluorescence (mIF) can assess internal states of individual cells along with their spatial locations, which is critical for deciphering how tumors interact with the immune system. The resulting insights, often referred to as the “grammar” of the tumor microenvironment, can help predict whether a tumor will respond to immunotherapy. If it is unlikely to respond, these insights can also inform strategies to reprogram the tumor from “cold” to “hot,” increasing its susceptibility to treatment.
This is exciting, but progress is hindered by the high cost and limited scalability of current technology. For example, obtaining mIF data of a couple dozen protein channels for a tissue sample can cost thousands…
